IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-04-23 (fiercebiotech.com)
Ken Park, MD |
Ken has spent two decades in healthcare, focusing on innovative businesses and solutions for the life sciences industry. He advises clients on R&D strategy and leads Fortrea's productivity initiatives. At McKinsey & Co., he pioneered Real World Evidence in Life Sciences and co-led big data applications in healthcare. As VP at Elevance, he managed Carelon's operations and launched CalINDEX, a Health Information Exchange. At IQVIA, he built new business lines in data, R&D services, and genomics. |
Read more
2025-04-10 (mzdrowie.pl)
Investments of pharmaceutical companies in research on new drugs increased -
This year's IQVIA Institute report on global trends in the biofarmaceutical industry shows the growing financing and modernization of the research facilities. Despite the biggest ones
Read more
2025-04-09 (pharma-fakten.de)
Clinical studies: Research on the drugs of tomorrow
Over 5,300 clinical studies have been restarted in 2024 worldwide. The focus is oncology, immunology, neurology and cardiovascular diseases.
Read more
2025-03-27 (plos.org)
Assessing concentration in the monoclonal antibody innovation market: A patent-based study | One
BACKGROUND Monoclonal antibodies (mAbs) are revolutionizing healthcare treatments due to their high efficacy and relative safety, despite their cost. Since they first appeared in the late 1980s, a rapidly growing market has developed. OBJECTIVE This study aims to analyze concentration levels in the market for mAb innovations through a quantitative patent analysis. Data were analyzed using traditional concentration indicators such as the Herfindahl-Hirschman Index and Concentration Ratio, as well as linear regression and kernel density graphs to evaluate innovation and global technology dissemination strategies. The starting point was patents associated with mAbs registered by the FDA and identified in the IQVIA database up until 2019, and supplemented by data from The Antibody Society, Purple Book, Orange Book, and FDA. RESULTS Our findings indicate that the market for mAb innovations is moderately concentrated for general patents and unconcentrated for priority patents. However, it is significantly more
Read more
2025-03-26 (consalud.es)
Investment in biopharmaceutical R&D increases 2,874 million euros in a single year
A new IQVIA report on research in the biopharmaceutical sector includes a remarkable increase in investment but a 17% decrease in the start of clinical trials since 2021, returning to prepaandemics levels
Read more
2025-02-18 (business-people.es)
Criteriacaixa brings to light his investment portfolio in the US
Until now, the La Caixa investment arm, Criteriacaixa, played the mystery with part of its international investments.
Read more
2025-01-30 (biotecnika.org)
IQVIA Clinical Research Coordinator Job – Apply Online
IQVIA Clinical Research Coordinator Job – Apply Online. IQVIA Clinical Research Job Openings. Clinical Research Careers.
Read more
2025-01-22 (technologynetworks.com)
Raja Shankar Editors |
As the VP for machine learning, Raja is focused on transforming life sciences and healthcare with the power of applied AI. He believes imagination is the biggest barrier and motivates his team to create new narratives that fully leverage AI’s potential to reshape the industry from R&D through to commercialization. Raja brings together a diverse set of technical and strategic capabilities, including machine learning, deep learning, generative AI, product development, life sciences expertise and business consulting skills. His team combines data science, domain expertise and consulting skills to drive impactful change by applying AI to life sciences and healthcare decisions. Raja is a trusted advisor to global life sciences companies, public sector clients and international organizations.
Read more
2024-12-29 (medicaldialogues.in)
IQVIA Gets CDSCO Panel Nod To conduct Phase III clinical Study of Lumateperone
New Delhi: IQVIA has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct a phase III clinical study of the...
Read more
2024-10-01 (ddw-online.com)
From data to cure: The journey of AI in cancer trials
Deepika Khedekar, Associate Centralized Clinical Trial Lead at IQVIA Inc, looks at the challenges of utilising artificial intelligence (AI) in oncology clinical research.
Read more
2024-09-30 (nature.com)
A standing platform for cancer drug development using ctDNA-based evidence of recurrence
The time required to conduct clinical trials limits the rate at which we can evaluate and deliver new treatment options to patients with cancer. New approaches to increase trial efficiency while maintaining rigor would benefit patients, especially in oncology, in which adjuvant trials hold promise
Read more
2024-09-20 (medianet.at)
Cost brake on generics
The Generics Association is drumming up advertising on its own behalf: it's about funding, prices and the ability to plan preparations.
Read more